PETVIVO TO EXHIBIT AND SPONSOR CANINE JOINT INJECTION LAB AT THE 2026 SOUTHWEST VETERINARY SYMPOSIUM IN SAN ANTONIO

PetVivo Holdings, Inc. (OTCQX:PETV)

MINNEAPOLIS, MN, UNITED STATES, September 9, 2026 /EINPresswire.com/ — PetVivo Animal Health, Inc. (“PetVivo”), in cooperation with its parent, PetVivo Holdings, Inc. (OTCQX: PETV), and its other subsidiaries, Somatrix Technologies, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for equine and companion animals announced today it will be exhibiting at the 2026 Southwest Veterinary Symposium (“SWVS”) to be held September 17th to September 20th 2026 at the Henry B. González Convention Center in San Antonio, Texas. In addition to exhibiting Spryng^® with OsteoCushion^® Technology at Booth 727, PetVivo is sponsoring the symposium’s Canine Joint Injection Lab, an interactive hands-on educational program for veterinarians focused on joint-injection techniques used in the management of canine osteoarthritis.

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology. Spryng is an intra-articular injectable veterinary medical device composed of sterilized extracellular matrix microparticles. The biocompatible microparticles are designed to work with synovial fluid to mimic the protective form and function of natural joint cartilage and assist in restoring proper joint mechanics. Spryng is intended for use in horses and companion animals to aid in the management of lameness, joint pain and osteoarthritis associated with joint dysfunction not caused by infection.

The Canine Joint Injection Lab will be held Friday, September 18, 2026, from 8:00 a.m. to 12:00 p.m. The sold-out interactive lab provides veterinarians with hands-on instruction and practice in canine joint-injection techniques. The lab complements PetVivo’s focus on providing veterinarians with innovative tools for the management of joint-related conditions, including osteoarthritis.

“The Southwest Veterinary Symposium provides an important opportunity for us to engage directly with veterinarians who are focused on improving the management of osteoarthritis and other joint-related conditions in their patients,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “We are particularly pleased to sponsor this year’s Canine Joint Injection Lab, which gives veterinarians the opportunity to gain hands-on experience with joint-injection techniques. This educational program aligns closely with our commitment to supporting veterinarians with innovative solutions such as Spryng with OsteoCushion Technology for the management of lameness, joint pain and osteoarthritis.”

For more information about PetVivo Holdings, Inc. and its innovative products please contact info1@petvivo.com or visit https://petvivo.com/, https://www.petvivoanimalhealth.com/ and https://www.sprynghealth.com.

Conference Details:
Southwest Veterinary Symposium Exhibit Details:
Booth/Table #: 727
Dates:
Thursday, September 17, 2026, 1:00pm – 4:00pm
Friday, September 18, 2026, 9:30am – 5:00pm
Saturday, September 19, 2026, 9:30am – 4:30pm
Location: The Henry B. González Convention Center, San Antonio, Texas
PetVivo-Sponsored Canine Joint Injection Lab:
Friday, September 18, 2026
8:00 a.m. – 12:00 p.m.
Location: Henry B. González Convention Center, San Antonio, Texas
Interactive Lab – Sold Out

About PetVivo Holdings, Inc.
PetVivo Holdings, Inc. (OTCQX: PETV), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI, Inc., is an emerging biomedical device company focused on the development, manufacturing, commercialization and licensing of innovative medical devices, biomaterials and therapeutics for animal and human health. The Company’s strategy is to leverage its proprietary technologies, intellectual property and scientific expertise to develop and commercialize products addressing unmet needs across veterinary and human medicine.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve issued and pending patents and six trade secrets protect the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product, SPRYNG^® with OsteoCushion^® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint-related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.

Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216

Forward-Looking Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

John Lai
Petvivo Holdings, Inc.
+1 (952) 405-6216
email us here
Visit us on social media:
LinkedIn
Facebook
YouTube

Media gallery

About The Author

Written By: EIN Presswire